title: Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
abstract: Multiple myeloma (MM) is associated with the development of osteolytic bone disease, mediated by increased osteoclastic bone resorption and impaired osteoblastic bone formation. Dickkopf-1 (Dkk1), a soluble inhibitor of wingless/int (Wnt) signaling and osteoblastogenesis, is elevated in patients with MM and correlates with osteolytic bone disease. In this study, we investigated the effect of inhibiting Dkk1 on the development of osteolytic lesions in the 5T2MM murine model of myeloma. We showed that Dkk1 is expressed by murine 5T2MM myeloma cells. Injection of 5T2MM cells into C57BL/KaLwRij mice resulted in the development of osteolytic bone lesions (p < 0.05), mediated by increased osteoclast numbers (p < 0.001) and a decrease in osteoblast numbers (p < 0.001) and mineralizing surface (p < 0.05). Mice bearing 5T2MM cells were treated with an anti-Dkk1 antibody (BHQ880, 10 mg/kg, IV, twice weekly for 4 wk) from time of paraprotein detection. Anti-Dkk1 treatment prevented 5T2MM-induced suppression of osteoblast numbers (p < 0.001) and surface (p < 0.001). Treatment increased mineralizing surface by 28% and bone formation rate by 25%; however, there was no change in mineral apposition rate. Inhibiting Dkk1 had no effect on osteoclast numbers. muCT analysis showed that anti-Dkk1 treatment significantly protected against 5T2MM-induced trabecular bone loss (p < 0.05) and reduced the development of osteolytic bone lesions (p < 0.05). Treatment had no significant effect on tumor burden. These data suggest that inhibiting Dkk1 prevents the suppression of bone formation and in doing so is effective in preventing the development of osteolytic bone disease in myeloma, offering an effective therapeutic approach to treating this clinically important aspect of myeloma.
authors.affiliation: Academic Unit of Bone Biology, Section of Musculoskeletal Sciences, University of Sheffield School of Medicine and Biomedical Sciences, Sheffield, Yorkshire, UK.
authors.forename: Deborah J
authors.initials: DJ
authors.lastname: Heath
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Chantry
authors.forename: Clive H
authors.initials: CH
authors.lastname: Buckle
authors.forename: Les
authors.initials: L
authors.lastname: Coulton
authors.forename: John D
authors.initials: JD
authors.lastname: Shaughnessy
authors.forename: Holly R
authors.initials: HR
authors.lastname: Evans
authors.forename: John A
authors.initials: JA
authors.lastname: Snowden
authors.forename: David R
authors.initials: DR
authors.lastname: Stover
authors.forename: Karin
authors.initials: K
authors.lastname: Vanderkerken
authors.forename: Peter I
authors.initials: PI
authors.lastname: Croucher
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002452:Cell Count; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D051379:Mice; D009101:Multiple Myeloma / Q000150:complications* / Q000473:pathology / Q000503:physiopathology*; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects; D010014:Osteolysis / Q000150:complications* / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D012995:Solubility / Q000187:drug effects; D047368:Tumor Burden / Q000187:drug effects; D051153:Wnt Proteins / Q000378:metabolism
chemical_list: D000906:Antibodies; C501126:DKK1 protein, human; C501127:Dkk1 protein, mouse; D036341:Intercellular Signaling Peptides and Proteins; D051153:Wnt Proteins